|Integrative Cancer Immunology · 15 Rue de l'Ecole de Medecine, 75006 Paris, France
Tel +33 1 4427 9101 · Fax +33 1 4427 8117 · URL http://www.ici.upmc.fr/index.shtml
|Immuno-Oncology Diagnostic company, Co-founder Dr. Jérôme Galon
HalioDx vision is to create a leader in Immuno-Oncology diagnostics, the emerging segment of the cancer molecular diagnostic market (MDx).
HalioDx plan is to develop a unique portfolio of MDx -IVDs solutions dedicated to Immuno-Oncology.
Dr. Jérôme Galon is a co-founder of HalioDx. The co-founders are experienced executives with extensive track records in the Diagnostic Industry, Pharma & BioTech Management.
The company is a spin-off of Qiagen Marseille, a subsidiary of Qiagen NV, previously known as Ipsogen, leader in developing MDx-IVDs for blood-based cancers.
Dr. Jérôme Galon
Co-founder of HalioDx
HalioDx has a unique Immuno-Oncology (I-O) technology. HalioDx licenced a comprehensive patent portfolio from Dr. Jérôme Galon & colleagues (INSERM UMRS1138), covering clinical use of I-O biomarkers, ImmunoscoreTM concept (IHC) & gene expression signatures (MDx), Assays & biomarkers correlated to prognosis and/or response to cancer therapeutics, with patents granted in US, EU and Japan.|
HalioDx has State of the art R&D, manufacturing facilities and expertise, with IVD compliant Quality System / ISO 13 485/ GMP, Fully qualified and trained staff (75 FTEs), and 1800 m2 of compliant R&D & manufacturing facilities.
Companies and institutions seeking to find out more about ImmunoscoreTM and IVD solutions, MDx and compagnion diagnostics CDx can directly contact HalioDx through: